Literature DB >> 12359604

Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.

Carol L Shields1, Masood Naseripour, Jacqueline Cater, Jerry A Shields, Hakan Demirci, Asraf Youseff, Jorge Freire.   

Abstract

OBJECTIVE: To assess treatment complications and tumor control after plaque radiotherapy for large posterior uveal melanomas measuring 8 mm or greater in thickness.
DESIGN: Prospective noncomparative interventional case series. PARTICIPANTS: Three hundred fifty-four patients each of whom had a posterior uveal melanoma measuring 8 mm or greater in thickness treated with plaque radiotherapy. MAIN OUTCOME MEASURES: The four endpoints included (1) poor final visual acuity (20/200 or worse), (2) enucleation, (3) local tumor recurrence, and (4) metastasis. The clinical data regarding patient features, tumor features, and radiation parameters were analyzed for their impact on the four main outcomes using Cox proportional hazards regression models.
RESULTS: Using Kaplan-Meier estimates, final visual acuity was poor in 57% at 5 years and 89% at 10 years follow-up. Using multivariate analysis, the most important risk factors for poor visual acuity included retinal invasion by melanoma, increasing patient age, iodine 125 (I(125)) isotope, and <2 mm distance to the optic disc. Treatment-related complications at 5 years included proliferative retinopathy (25%), maculopathy (24%), papillopathy (22%), cataract (66%), neovascular glaucoma (21%), vitreous hemorrhage (23%), and scleral necrosis (7%). Enucleation was necessary in 24% at 5 years and 34% at 10 years follow-up. Using multivariate analysis, the risk factors for enucleation included left eye, peripheral tumor margin anterior rather than posterior to the equator, increasing tumor thickness, and ruthenium 106 (Ru(106)) isotope. Using Kaplan-Meier estimates, local tumor recurrence was found in 9% at 5 years and 13% at 10 years follow-up. Using multivariate analysis, risk factors for tumor recurrence included Ru(106) radioisotope and ciliary body involvement with tumor. Tumor-related metastases were found in 30% at 5 years and 55% at 10 years follow-up. Using multivariate analysis, risk factors for metastases included inferotemporal meridian, anterior extension of the tumor to the iris root, increasing tumor base, and posterior margin < 2 mm from the optic nerve.
CONCLUSIONS: Plaque radiotherapy provided tumor control at 10 years in 87% of patients with selected large posterior uveal melanomas (>8 mm thick) that otherwise would have been managed with enucleation. The large intraocular mass and associated features and radiation complications led to poor visual acuity in most patients. At 10 years follow-up, enucleation was necessary in 34% of patients, and metastasis developed in 55% of patients.

Entities:  

Mesh:

Year:  2002        PMID: 12359604     DOI: 10.1016/s0161-6420(02)01181-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  35 in total

1.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

Review 2.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

3.  23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity.

Authors:  Tara A McCannel; Mitchell Kamrava; Jeffrey Demanes; James Lamb; John D Bartlett; Robert Almanzor; Melissa Chun; Colin A McCannel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-16       Impact factor: 3.117

4.  Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.

Authors:  Ivana K Kim; Anne Marie Lane; Purva Jain; Caroline Awh; Evangelos S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

5.  Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications.

Authors:  Klaus-Martin Kreusel; Nikolaos Bechrakis; Juliane Riese; Lothar Krause; Joachim Wachtlin; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

Review 6.  [CyberKnife®: new treatment option for uveal melanoma].

Authors:  J M Mor; R Semrau; W Baus; K R Koch; F Schaub; C Cursiefen; S Marnitz; L M Heindl
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

Review 7.  Emerging treatments for choroidal metastases.

Authors:  Connie J Chen; Allison N McCoy; Julie Brahmer; James T Handa
Journal:  Surv Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 6.048

8.  Long-term Outcomes After Proton Beam Irradiation in Patients With Large Choroidal Melanomas.

Authors:  Thanos D Papakostas; Anne Marie Lane; Margaux Morrison; Evangelos S Gragoudas; Ivana K Kim
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

9.  Exoresection and endoresection for uveal melanoma.

Authors:  Kaan Gündüz; Nikolaos E Bechrakis
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

10.  Scleral necrosis after radiation therapy for uveal melanomas: report of 23 cases.

Authors:  Pietro P Radin; Livia Lumbroso-Le Rouic; Christine Levy-Gabriel; Rémi Dendale; Xavier Sastre; Laurence Desjardins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.